S'abonner

Detection of SARS-CoV-2 RNA in fecal specimens of patients with confirmed COVID-19: A meta-analysis - 25/07/20

Doi : 10.1016/j.jinf.2020.06.012 
Martin CS Wong a, , Junjie Huang a, , Christopher Lai b, Rita Ng b, Francis K.L. Chan c, d, Paul K.S. Chan b, d,
a JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China 
b Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, 1/F, Clinical Sciences Building, Prince of Wales Hospital, Shatin, N.T. Hong Kong SAR, China 
c Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China 
d Centre for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China 

Corresponding author at: Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, 1/F, Clinical Sciences Building, Prince of Wales Hospital, Shatin, N.T. Hong Kong SAR, China.Department of MicrobiologyFaculty of MedicineThe Chinese University of Hong Kong1/F, Clinical Sciences Building, Prince of Wales HospitalShatinN.T. Hong Kong SARChina1These first authors contributed equally to this article.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Highlights

We examined the detection rate of SARS-CoV-2 RNA in specimens of COVID-19 patients.
The pooled detection rate of the RNA was 43.7% (by patient) and 33.7% by specimens.
Female patients, those with symptoms or more severe disease had higher detection rate.
Infection control strategies on fecal spread and contamination are urgently needed.

Le texte complet de cet article est disponible en PDF.

Abstract

Introduction

Recent studies showed that SARS-CoV-2 RNA may be found in fecal specimens of COVID-19 patients, but the sample size is limited. This systematic review and meta-analysis examined the detection rate of SARS-CoV-2 RNA in fecal specimens of these patients according to their clinical characteristics.

Methods

MEDLINE, Embase, Scopus, and three Chinese biomedical databases were searched up to 25 March 2020 with no language restriction. We included original observational studies that reported the detection rate of SARS-CoV-2 RNA in fecal specimens of COVID-19 patients. Two separate reviewers conducted the review. Metaprop was adopted to conduct a meta-analysis of prevalence with variances stabilized by Freeman-Tukey Double Arcsine Transformation. A random-effects model was used. Heterogeneity across different studies was computed using Cochran's Q test and chi square statistics.

Results

From 17 studies, the pooled detection rate of fecal SARS-CoV-2 RNA was 43.7% (95% CI 32.6%-55.0%) and 33.7% (95% C.I. 33.7%, 95% C.I. 20.1%-48.8%) by patient and number of specimens as a unit count, respectively. Female individuals (59.6% vs. 53.5%), those who presented with gastrointestinal symptoms (77.1% vs. 57.7%), and patients with more severe disease (68.3% vs. 34.6%) tended to have a higher detection rate.

Discussion

A significant proportion of COVID-19 patients carry SARS-CoV-2 in their intestinal tract. Feces being a self-collected specimen bears a potential to improve case identification in community, especially for young children where proper respiratory sampling at home is difficult. Specific infection control strategies focusing on spread via fecal contamination and faulty toilet drainage are urgently needed.

Le texte complet de cet article est disponible en PDF.

Keywords : COVID-19, SARS-CoV-2, detection rate, faecal specimen, meta-analysis


Plan


© 2020  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 81 - N° 2

P. e31-e38 - août 2020 Retour au numéro
Article précédent Article précédent
  • Clinical and epidemiological features of COVID-19 family clusters in Beijing, China
  • Rui Song, Bing Han, Meihua Song, Lin Wang, Christopher P. Conlon, Tao Dong, Di Tian, Wei Zhang, Zhihai Chen, Fujie Zhang, Mang Shi, Xingwang Li
| Article suivant Article suivant
  • Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients
  • E Tuaillon, K Bolloré, A Pisoni, S Debiesse, C Renault, S Marie, S Groc, C Niels, N Pansu, AM Dupuy, D Morquin, V Foulongne, A Bourdin, V Le Moing, P Van de Perre

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.